[go: up one dir, main page]

ES2068762B1 - Un nuevo preparado farmaceutico para mejorar la biodisponibilidad de drogas de dificil absorcion y procedimiento para su obtencion. - Google Patents

Un nuevo preparado farmaceutico para mejorar la biodisponibilidad de drogas de dificil absorcion y procedimiento para su obtencion.

Info

Publication number
ES2068762B1
ES2068762B1 ES09301637A ES9301637A ES2068762B1 ES 2068762 B1 ES2068762 B1 ES 2068762B1 ES 09301637 A ES09301637 A ES 09301637A ES 9301637 A ES9301637 A ES 9301637A ES 2068762 B1 ES2068762 B1 ES 2068762B1
Authority
ES
Spain
Prior art keywords
procedure
bioavailability
drugs
obtaining
improve
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES09301637A
Other languages
English (en)
Other versions
ES2068762A1 (es
Inventor
Garces Jose Santos Garces
Munoz Angel Bonilla
Anton Jose Maria Garcia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GP Pharm SA
Original Assignee
Lipotec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES09301637A priority Critical patent/ES2068762B1/es
Application filed by Lipotec SA filed Critical Lipotec SA
Priority to EP94500128A priority patent/EP0635261B1/en
Priority to AT94500128T priority patent/ATE178205T1/de
Priority to DE69417481T priority patent/DE69417481T2/de
Priority to DK94500128T priority patent/DK0635261T3/da
Priority to JP16790694A priority patent/JP4480801B2/ja
Priority to US08/278,520 priority patent/US5736161A/en
Publication of ES2068762A1 publication Critical patent/ES2068762A1/es
Application granted granted Critical
Publication of ES2068762B1 publication Critical patent/ES2068762B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

UN NUEVO PREPARADO FARMACEUTICO PARA MEJORAR LA BIODISPONIBILIDAD DE DROGAS DE DIFICIL ABSORCION Y PROCEDIMIENTO PARA SU OBTENCION. EL PREPARADO ESTA COMPUESTO DE MILIESFERAS, MICROESFERAS, NANOESFERAS, O PARTICULAS MATRICIALES FORMADAS POR UN NUCLEO DE UN HIDROCOLOIDE GELIFICABLE SOBRE EL QUE SE HA DEPOSITADO UNA PELICULA DE UN POLISACARIDO CATIONICO, INCORPORANDO EN SU INTERIOR UNA DROGA DE INTERES FARMACOLOGICO. EL PROCEDIMIENTO COMPRENDE DISOLVER, SUSPENDER O EMULSIONAR LA DROGA EN UNA DISOLUCION DEL HIDROCOLOIDE; AÑADIR LA MEZCLA RESULTANTE A UNA SOLUCION GELIFICANTE; Y SUSPENDER LAS MILIESFERAS, MICROESFERAS O NANOESFERAS RESULTANTES EN UNA DISOLUCION DEL POLISACARIDO CATIONICO.
ES09301637A 1993-07-21 1993-07-21 Un nuevo preparado farmaceutico para mejorar la biodisponibilidad de drogas de dificil absorcion y procedimiento para su obtencion. Expired - Fee Related ES2068762B1 (es)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ES09301637A ES2068762B1 (es) 1993-07-21 1993-07-21 Un nuevo preparado farmaceutico para mejorar la biodisponibilidad de drogas de dificil absorcion y procedimiento para su obtencion.
AT94500128T ATE178205T1 (de) 1993-07-21 1994-07-19 Überzogene mikropartikel mit verbesserter arzneistoffabsorption
DE69417481T DE69417481T2 (de) 1993-07-21 1994-07-19 Überzogene Mikropartikel mit verbesserter Arzneistoffabsorption
DK94500128T DK0635261T3 (da) 1993-07-21 1994-07-19 Coatede mikropartikler med forbedret lægemiddelabsorption
EP94500128A EP0635261B1 (en) 1993-07-21 1994-07-19 Coated microparticles with improved drug absorption
JP16790694A JP4480801B2 (ja) 1993-07-21 1994-07-20 吸収困難な薬剤の生物学的利用能を改善する製剤およびそれを生成する方法
US08/278,520 US5736161A (en) 1993-07-21 1994-07-21 Pharmaceutical preparation for improving the bioavailability of drugs which are difficult to absorb and a procedure for obtaining it

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES09301637A ES2068762B1 (es) 1993-07-21 1993-07-21 Un nuevo preparado farmaceutico para mejorar la biodisponibilidad de drogas de dificil absorcion y procedimiento para su obtencion.

Publications (2)

Publication Number Publication Date
ES2068762A1 ES2068762A1 (es) 1995-04-16
ES2068762B1 true ES2068762B1 (es) 1995-12-01

Family

ID=8282628

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09301637A Expired - Fee Related ES2068762B1 (es) 1993-07-21 1993-07-21 Un nuevo preparado farmaceutico para mejorar la biodisponibilidad de drogas de dificil absorcion y procedimiento para su obtencion.

Country Status (7)

Country Link
US (1) US5736161A (es)
EP (1) EP0635261B1 (es)
JP (1) JP4480801B2 (es)
AT (1) ATE178205T1 (es)
DE (1) DE69417481T2 (es)
DK (1) DK0635261T3 (es)
ES (1) ES2068762B1 (es)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5938990A (en) * 1994-07-01 1999-08-17 Roche Vitamins Inc. Encapsulation of oleophilic substances and compositions produced thereby
US6992107B1 (en) 1995-03-10 2006-01-31 Photocure Asa Esters of 5-aminolevulinic acid and their use as photosensitizing compounds in photochemotherapy
ATE192334T1 (de) 1995-11-09 2000-05-15 Microbiological Res Authority Mikroverkapselte dna zur impfung und gentherapie
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
US5783567A (en) * 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
WO1998048626A1 (en) * 1997-04-30 1998-11-05 Emory University Methods and compositions for administering dna to mucosal surfaces
GB9710699D0 (en) 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
WO1999012571A1 (en) * 1997-09-05 1999-03-18 Maruho Kabushikikaisha Nanocapsule preparations for treating intraarticular diseases
IN186245B (es) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6090368A (en) * 1998-03-03 2000-07-18 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Pharmaceutical compositions for intranasal spray administration of ketorolac tromethamine
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6548302B1 (en) 1998-06-18 2003-04-15 Johns Hopkins University School Of Medicine Polymers for delivery of nucleic acids
US6916490B1 (en) 1998-07-23 2005-07-12 UAB Research Center Controlled release of bioactive substances
RU2236847C2 (ru) * 1998-11-02 2004-09-27 Илан Корпорейшн, Плк. Композиции в виде множества частиц с модифицированным высвобождением
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
DK1154759T3 (da) 1998-12-30 2008-12-08 Dexcel Ltd Dispergerbart koncentrat til indgift af cyclosporin
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
EP1080719A3 (en) * 1999-09-03 2001-04-25 Active Organics Inc. Methods for potentiation of efficacy of topical actives by mono-acyl-(lyso)-glycerophosholipids
US6369037B1 (en) 1999-10-19 2002-04-09 Cornell Research Foundation, Inc. Controlled release of doxorubicin
ES2162746B1 (es) * 1999-10-21 2003-02-16 Lipotec Sa Microcapsulas para la estabilizacion de productos cosmeticos, farmaceuticos o de alimentacion.
AU8008300A (en) * 1999-11-01 2001-05-14 Alcon Inc. Pharmaceutical compositions containing a fluoroquinolone antibiotic drug and xanthan gum
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
DE10021894A1 (de) * 2000-05-05 2001-11-29 Ilias Papadopoulos Pharmazeutisches Präparat zur Diagnose und Behandlung der erektilen Dysfunktion
KR20020018566A (ko) * 2000-09-01 2002-03-08 액티브 올가닉스 인코포레이티드 모노-아실-(리소)-글리세롤인지질로 국소 활성의 효능을강화하는 방법 및 이의 용도
ITMI20010347A1 (it) * 2001-02-21 2002-08-21 Grisotech S A Complessi di immunoglobuline e polisaccaridi per assorbimento orale etrans-mucosale
WO2003064621A2 (en) * 2002-02-01 2003-08-07 Ambion, Inc. HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
BR0308990A (pt) * 2002-04-03 2005-01-04 Ranbaxy Lab Ltd Composição farmacêutica de eritromicina e seus derivados com sabor mascarado e processo de sua preparação
US7858607B2 (en) * 2003-03-14 2010-12-28 Mamchur Stephen A System for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US20070196396A1 (en) * 2004-02-11 2007-08-23 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
JP2009517485A (ja) * 2005-06-08 2009-04-30 エラン・ファルマ・インターナショナル・リミテッド セフジトレンを含むナノ粒子状および制御放出組成物
US20060293236A1 (en) * 2005-06-23 2006-12-28 Prescott Albert G Injectable Osteogenic Formula and Method of Using Same
US20070082030A1 (en) * 2005-10-07 2007-04-12 Aimutis William R Fiber satiety compositions
US20070082029A1 (en) * 2005-10-07 2007-04-12 Aimutis William R Fiber satiety compositions
FR2897267A1 (fr) * 2006-02-16 2007-08-17 Flamel Technologies Sa Formes pharmaceutiques multimicroparticulaires pour administration per os
US20070224153A1 (en) * 2006-03-16 2007-09-27 Librizzi Joseph J High-deposition compositions and uses thereof
US20070218029A1 (en) * 2006-03-16 2007-09-20 Librizzi Joseph J High-deposition compositions and uses thereof
KR20080111033A (ko) * 2006-03-29 2008-12-22 후지필름 가부시키가이샤 카제인 나노입자
MX2008012678A (es) * 2006-04-07 2008-12-17 Merrion Res Iii Ltd Forma de dosis oral solida que contiene un mejorador.
WO2007146234A2 (en) * 2006-06-09 2007-12-21 Merrion Research Ii Limited Solid oral dosage form containing an enhancer
US20080085354A1 (en) * 2006-10-06 2008-04-10 Teresa Marie Paeschke Controlled hydration of hydrocolloids
US20090035236A1 (en) * 2007-07-31 2009-02-05 Maes Daniel H Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And An Oil Phase Structuring Agent
US8080583B2 (en) 2007-07-31 2011-12-20 Elc Management Llc Emulsion cosmetic compositions containing resveratrol derivatives and linear or branched silicone
US20090035240A1 (en) * 2007-07-31 2009-02-05 Maes Daniel H Aqueous Based Cosmetic Compositions Containing Resveratrol Derivatives And An Aqueous Phase Structuring Agent
US8344024B2 (en) * 2007-07-31 2013-01-01 Elc Management Llc Anhydrous cosmetic compositions containing resveratrol derivatives
US9295621B2 (en) * 2007-07-31 2016-03-29 Elc Management Llc Emulsion cosmetic compositions containing resveratrol derivatives and silicone surfactant
US20130079749A1 (en) * 2007-08-29 2013-03-28 Advanced Bionics, Llc Modular Drug Delivery System for Minimizing Trauma During and After Insertion of a Cochlear Lead
CN101854903B (zh) * 2007-09-08 2012-07-04 Elc管理有限责任公司 阿魏酸白藜芦醇酯化合物、包含该化合物的组合物及其使用方法
CA2718416C (en) * 2008-03-13 2018-01-02 Mallinckrodt Inc. Multi-function, foot-activated controller for imaging system
CA2723541A1 (en) * 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
TWI480286B (zh) * 2009-02-25 2015-04-11 Merrion Res Iii Ltd 雙膦酸鹽類組合物及藥物遞送
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011120033A1 (en) * 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
CA2819234A1 (en) 2011-01-07 2012-07-12 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
CA2899664C (en) * 2012-03-20 2019-07-09 Laboratorios Bago S.A. Method for producing enteric alginate microcapsules via ionic gelation containing diclofenac or one of the salts thereof and multiparticled pharmaceutical composition containing them
WO2014167554A2 (en) * 2013-04-12 2014-10-16 Vyome Biosciences Pvt. Ltd. Composition and formulation of antimicrobial agents, processes thereof and methods for treating microbial infections
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016120378A1 (en) 2015-01-29 2016-08-04 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12150945B2 (en) 2018-07-20 2024-11-26 Lipocine Inc. Liver disease
WO2020212952A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Treatment of depression and other various disorders with psilocybin
CN116869945A (zh) * 2023-08-28 2023-10-13 郑州大学 一种内镜黏膜下海藻酸钠载药微球注射液及其制备方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA301777A (en) * 1930-07-08 Russell Bates David Preheater for boiler feed water
JPS6164701A (ja) * 1984-09-06 1986-04-03 Meito Sangyo Kk カチオン化デキストラン誘導体とポリウロン酸の高分子電解質錯体及びその利用
AU591248B2 (en) * 1986-03-27 1989-11-30 Kinaform Technology, Inc. Sustained-release pharaceutical preparation
DE3615043A1 (de) * 1986-05-03 1987-11-05 Hoechst Ag Verfahren zur verkapselung von biologisch aktivem material
EP0301777A1 (en) * 1987-07-28 1989-02-01 Queen's University At Kingston Multiple membrane microencapsulation
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
GB2237510B (en) * 1989-11-04 1993-09-15 Danbiosyst Uk Small particle drug compositions for nasal administration
SE9002339L (sv) * 1990-07-04 1992-01-05 Kabi Pharmacia Ab Terapeutisk komposition och foerfarande foer dess framstaellning
US5215757A (en) * 1991-03-22 1993-06-01 The Procter & Gamble Company Encapsulated materials
IT1260505B (it) * 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon

Also Published As

Publication number Publication date
DE69417481T2 (de) 1999-11-25
JPH07145044A (ja) 1995-06-06
ATE178205T1 (de) 1999-04-15
DE69417481D1 (de) 1999-05-06
ES2068762A1 (es) 1995-04-16
US5736161A (en) 1998-04-07
JP4480801B2 (ja) 2010-06-16
EP0635261A1 (en) 1995-01-25
EP0635261B1 (en) 1999-03-31
DK0635261T3 (da) 1999-10-18

Similar Documents

Publication Publication Date Title
ES2068762B1 (es) Un nuevo preparado farmaceutico para mejorar la biodisponibilidad de drogas de dificil absorcion y procedimiento para su obtencion.
CR6656A (es) Forma de dosificacion de farmacos accionada por un hidrogel
AR025959A1 (es) DERIVADOS DE TER.-BUTIL-(7-METIL-IMIDAZO[1,2,a]PIRIDIN-3-IL)-AMINA, PROCEDIMIENTO PARA SU PREPARACION, MEDICAMENTOS QUE LOS CONTIENEN, SU USO PARA LAPREPARACION DE UN MEDICAMENTO PARA LA INHIBICION DE NO-SINTASA Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
ES2114423B1 (es) Nuevas composiciones farmaceuticas de liberacion de farmaco controlada por difusion-osmosis y procesos para preparar las mismas.
BR0009770A (pt) Derivados de bisindóis indigóides capazes de penetrarem na membrana de células, formulação farmacêutica e utilização da mesma
AR008553A1 (es) Forma de dosificacion farmaceutica que enmascara el sabor y que se libera rapidamente.
ATE247115T1 (de) Substituierte stickstoff-heterocyclische derivate und deren pharmazeutische verwendung
BR0016012A (pt) Implante farmacêutico contendo componentes de liberação imediata e de liberação prolongada, além de processo de administração
BRPI0408396A (pt) pelìculas de dissolução rápida, consumìveis por via oral, contendo agentes farmaceuticamente ativos
ECSP044974A (es) Formulación de suspensión oral estabilizada
Prakash et al. Preparation and characterization of lamivudine microcapsules using various cellulose polymers
HUP0203451A2 (hu) Új, tuberkolózis elleni gyógyszerkészítmények és eljárás előállításukra
AR029175A1 (es) Derivados 2-amino-fenilpurina, un proceso para su preparacion, composicion farmaceutica que los comprende, y el uso de los mismos para la preparacion de un medicamento
ATE152620T1 (de) Pharmazeutischer träger
CL2011003046A1 (es) Composicion farmaceutica que comprende 7-(2,5-dihidro-4-imidazo[1,2-a]-piridin-3-il-2,5-dioxo-1h-pirrol-3-il)-9-fluoro-1,2,3,4-tetrahidro-2-(1-piperidinil-carbonil)pirrolo[3,2,1-jk] [1,4]benzodiazepina, una sal o solvato, sbe7-b-cd y opcionalmente un tampon; proceso de preparacion; util para tratar cancer (div. sol. 1848-08).
BR9913562A (pt) Derivados de benzeno, inibidor de ativação de ap-1 e nf-capa b, inibidor de produção de citoquina inflamatória, inibidor de produção de metaloprotease matricial ou inibidor de aparecimento de fator de adesão de célula inflamatório, e, agente antiinflamatório, anti-reumático, imunossupressor, inibidor de metástase cancerosa, remédio para arterioesclerose e agente antiviral
BR0014826A (pt) Imidazo-3-il-aminas bicìclicas, procedimento de sua preparação e medicamentos que as contêm
EA200401369A1 (ru) Замедленно высвобождающие лекарственные композиции гвайфенезина
EP1334732A4 (en) PHARMACEUTICAL PREPARATION WITH COPOLYVIDONE
WO2005065648A3 (en) Novel drug compositions and dosage forms of topiramate
AR003114A1 (es) Uso de polisacaridos sulfatados para la preparacion de un medicamento para la inhibicion de infeccion de rotavirus y composicion que los contienen
MX171030B (es) Formulaciones farmaceuticas de liberacion prolongada, liquidas, que contienen constituyentes ionicos
CO4750645A1 (es) Metodo de preparacion de granulos que incorporan un medica- mento para uso farmaceutico
CO4970742A1 (es) Suspension farmaceutica que comprende hemihidrato de nevipa- rina
Pai et al. Formulation and evaluation of extended release ocular inserts prepared from synthetic and natural biodegradable-biocompatible polymers

Legal Events

Date Code Title Description
PC2A Transfer of patent

Owner name: GP-PHARM, S.A.

Effective date: 20120906

FD2A Announcement of lapse in spain

Effective date: 20141120